|

ADT Clinical Trials

9 actively recruiting trials across 5 locations

▲ +1 trial since August 2026

Also known as: Androgen Deprivation Therapy, Androgen deprivation therpay, Hormone Therapy

Pipeline

Phase 2: 4Phase 3: 2Phase 1/2: 2

Top Sponsors

  • Canadian Cancer Trials Group2
  • Bayer2
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
  • Peter Busch Østergren1
  • National Cancer Institute (NCI)1

Indications

  • Cancer9
  • Prostate Cancer3
  • High-Risk Localized Prostate Cancer1
  • Non-metastatic Castration-resistant Prostate Cancer1
  • Prostate Neoplasms1

Other4 trials

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
Phase 2
An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment
National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients
Phase 1/2
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Phase 2

Anchorage, Alaska1 trial

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Anchorage Associates in Radiation Medicine

Phase 3

Antioch, California1 trial

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Kaiser Permanente-Deer Valley Medical Center

Phase 3

Duarte, California1 trial

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

City of Hope Medical Center

Phase 2

Bethesda, Maryland1 trial

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

National Institutes of Health Clinical Center

Phase 1/2

Houston, Texas1 trial

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.